Home › Research › Clinical trials
Effects of combination estrogen plus progestin hormone treatment on cognition and affect
Resnick SM, Maki PM, Rapp SR, Espeland MA, Brunner R, Coker LH, Granek IA, Hogan P et al.. The Journal of clinical endocrinology and metabolism, 2006-03-07
Topic: Brain proteins, microglia and lab models
Plain-language summary
Context Some studies of hormone treatment in postmenopausal women suggest benefits on specific cognitive functions, particularly memory. Objective The objective of this study was to determine whether hormone therapy influences changes in specific cognitive functions and affect in older women. Design This study was a randomized, double-blind, placebo-controlled clinical trial. Setting Participants were women from 14 of 40 clinical centers of the Women's Health Initiative (WHI). Participants Postmenopausal women (1416) aged 65 yr and older, free of probable dementia, and enrolled in WHI and the WHI Memory Study (WHIMS) trial of combination estrogen and progestin for a mean of 3 yr and followed for a mean of 1.35 yr, were studied. Intervention Intervention was conjugated equine estrogen (CEE; 0.625 mg) with 2.5 mg medroxyprogesterone acetate (MPA) in one daily tablet (CEE + MPA) or placebo. Main outcome measures Annual rates of change in specific cognitive functions and affect, adjusted for time since randomization, were measured. Results CEE + MPA had a negative impact on verbal memory (P <or= 0.01) and a trend to a positive impact on figural memory (P = 0.012) over time compared with placebo, but other cognitive domains were not affected. Both effects on memory were evident only after long-term therapy. CEE + MPA did not significantly influence positive affect, negative affect, or depressive symptoms. Conclusions The effect of CEE + MPA on cognitive function varies across cognitive domains in older women, reflecting both possible beneficial and detrimental actions of ovarian steroids on the aging brain. Our results extend prior findings about dementia and global cognitive function to age-related changes in specific cognitive functions and suggest directions for future research.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Resnick, S. M., Maki, P. M., Rapp, SR., Espeland, M. A., Brunner, R., Coker, L. H., et al. (2006). Effects of combination estrogen plus progestin hormone treatment on cognition and affect. The Journal of clinical endocrinology and metabolism. https://doi.org/10.1210/jc.2005-2097
Vancouver
Resnick SM, Maki PM, Rapp SR, Espeland MA, Brunner R, Coker LH, et al. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. The Journal of clinical endocrinology and metabolism. 2006. doi:10.1210/jc.2005-2097. PMID: 16522699.
BibTeX
@article{resnick2006-16522699,
author = {Resnick, S. M. and Maki, P. M. and Rapp, SR. and Espeland, M. A. and Brunner, R. and Coker, L. H. and Granek, I. A. and Hogan, P. and others},
title = {{Effects of combination estrogen plus progestin hormone treatment on cognition and affect}},
journal = {The Journal of clinical endocrinology and metabolism},
year = {2006},
doi = {10.1210/jc.2005-2097},
pmid = {16522699},
url = {https://doi.org/10.1210/jc.2005-2097}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results CEE + MPA had a negative impact on verbal memory (P <or= 0.01) and a trend to a positive impact on figural memory (P = 0.012) over time compared with placebo, but other cognitive domains were not affected.
- CEE + MPA did not significantly influence positive affect, negative affect, or depressive symptoms.
- Our results extend prior findings about dementia and global cognitive function to age-related changes in specific cognitive functions and suggest directions for future research.
New to this subject? Start with our plain-English guide: Registered clinical trials →
Study details
- Effect sizeor= 0.01
- Evidence strengthHigh
How this study scored 74/100
Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for sample size because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 43 of the 58 points we could judge it on, which is 74 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The Journal of clinical endocrinology and metabolism) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2006 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (pubmed indexes it as a clinical or observational study) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 16522699) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 43 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 43 of the 58 points we could judge it on is 74 out of 100. |
| Total | 74 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Clinical trials from nearby years
Also tagged “estrogen”
5 studies in the library carry the topic tag “estrogen”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 5 tagged studies.